1. https://clinicaltrials.gov/
2. 2019 年版世界の核酸医薬品開発の現状と将来展望, シードプランニング, 2019.
3. Zamecnik, P.C., Stephenson, M.L. (1978) Inhibition of Rous sarcoma virus replication and cell
transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA, 75, 280-284.
4. Stephenson, M.L., Zamecnik, P.C. (1978) Inhibition of Rous sarcoma viral RNA translation by a specific
oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA, 75, 285-288.
5. Crook, S.T. (2008) Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edition,
Marcel Dekker, New York.
6. Bennett, F.C. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense
oligonucleotides as a therapeutic platform. Annu. Rev., 50, 259-293.
7. Lindow, M. and Kauppinen, S. (2012) Discovering the first microRNA-targeted drug. J. Cell Biol., 199,
407-412.
8. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug
Metab. Toxicol., 5, 381-391.
9. Obika, S., Morio, K., Nanbu, D. and Imanishi, T. (1997) Synthesis and conformation of 3’-O,4’-Cmethyleneribonucleosides, novel bicyclic nucleoside analogues for 2’, 5’-linked oligonucleotide
modification. Chem. Commun., 17, 1643-1644
10. Koshkin, A.A., Singh, S.K., Nielsen, P., Rajwanshi, V.K., Kumar, R., Meldgaard, M., Olsen, C.E. and
Wengel, J. (1998) LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented
72
nucleic acid recognition. Tetrahedron, 54, 3607-3630
11. Seth, P.P., A Siwkowski, C.R., Allerson, G., Vasquez, S., Lee, T.P., Prakash, E.V., Wancewicz, D. (2009)
Short antisense oligonucleotides with novel 2’-4’ conformationaly restricted nucleoside analogues show
improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
12. Turchi, J.J., Huang, L., Murante, R.S., Kim, Y. and Bambara, R.A. (1994) Enzymatic completion of
mammalian lagging-strand DNA replication. Proc. Natl Acad. Sci. USA, 91, 9803-9807.
13. Lazzaro, F., Novarina, D., Amara, F., Watt, D.L., Stone, J.E., Costanzo, V., Burgers, P.M., Kunkel, T.A.,
Plevani, P. and Muzi-Falconi, M. (2012) RNase H and postreplication repair protect cells from
ribonucleotides incorporated in DNA. Mol. Cell, 45, 99-110.
14. Cerritelli, S.M., Frolova, E.G., Feng, C., Grinberg, A., Love, P.E. and Crouch, R.L. (2003) Failure to
produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Mol. Cell, 11, 807-815.
15. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H. and Crooke, S.T. (2004) Determination of the role of
the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279, 17181-17189
16. Yu, R.Z., Geary, R.S., Flaim, J.D., Riley, G.C., Tribble, D.L., vanVliet, A.A. and Wedel, M.K. (2009)
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified
antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
Clin. Pharmacokinetics, 48, 39-50
17. Yu, R.Z., Kim, T., Hong, A., Watanabe, T.A., Gaus, H.J. and Geary R.S. (2007) Cross-species
pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS
301012, targeting human apolipoprotein B-100. Drug Metabol. Dis., 35, 460-468
18. Kastelein, J.J., Wedel, M.K., Baker, B.F., Su, J., Bradley, J.D., Yu, R.Z., Chuang, E., Graham, M.J. and
Crooke, R.M. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B. Circulation, 114, 1729-1735.
73
19. Dyck, P.K., Dyck, P.J., et al. (2017) Assessing mNIS+7Ionis and international neurologists' proficiency
in a familial amyloidotic polyneuropathy trial. Muscle Nerve., 56, 901-911.
20. Paik, J., Duggan, S. (2019) Volanesorsen: First Global Approval. Drugs., 79, 1349-1354.
21. Burel, S.A., SR Han, HS Lee, DA Norris, BS Lee, T Machemer, SY Park, T Zhou, G He, et al. (2013)
Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound
targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid
Ther., 23, 213-227.
22. Shen, X. and DR, Corey. (2017) Chemistry, mechanism and clinical status of antisense oligonucleotides
and duplex RNAs. Nucleic Acid Res., 46, 1584-1600.
23. Frazier, K. S., (2015) Antisense oligonucleotide therapies: the promise and the challenges from a
toxicologic pathologist’s perspective. Toxicol. Pathol., 43, 78–89.
24. ICH S6 対応研究班「核酸医薬品のオフターゲット作用の評価」医薬品医療機器レギュラトリ
ーサイエンス, 46, 681-686.
25. FDA Briefing Document, Mipomersen Sodium Injection 200 mg/mL (2012) NDA 203568
26. EMA public assessment report, Questions and answers on the refusal of the marketing authorisation for
Kynamro (Mipomersen Sodium) -Outcome of re-examination (2013) EMA/177547/2013
27. Food and Drug Administration Center for Drug evaluation and Research 2018,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf
28. Swayze, E.E., Siwkowski, A.M., Wancewicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., Hung, G.,
Monia, B.P. and Bennett, C.F. (2007) Antisense oligonucleotides containing locked nucleic acid improve
potency but cause significant hepatotoxicity in animals. Nucleic Acids Res., 35, 687-700.
74
29. Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., Walters, E., Kreeger, J.,
DiMattia, D., Chen, T., Clark, T., Liu, M., Qian, J., Roy, M. and Dullea, R. (2012) Chemical modification
study of antisense gapmers. Nucleic Acid Ther., 22, 344-559.
30. van Poelgeest, E.P., Swart, R.M., Betjes, M.G., Moerland, M., Weening, J.J., Tessier, Y., Hodges, M.R.,
Levin, A.A. and Burggraaf, J. (2013) Acute kidney injury during therapy with an antisense oligonucleotide
directed against PCSK9. Am. J. Kid. Dis., 62, 796-800.
31. Seth, P.P., Jazayeri, A., Yu, J., Allerson, C.R., Bhat, B. and Swayze, E.E. (2012) Structure activity
relationships of α-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol.
Ther. Nucleic. Acids., 1, e47.
32. Seth, P.P., Allerson, C.R., Berdeja, A., Siwkowski, A., Pallan, P.S., Gaus, H., Prakash, T.P., Watt, A.T.,
Egli, M. and Swayze, E.E. (2010) An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom
in LNA. J. Am. Chem. Soc., 132, 14942-14950.
33. Egli, M., Pallan, P.S., Allerson, C.R., Prakash, T.P., Berdeja, A., Yu, J., Lee, S., Watt, A., Gaus, H., Bhat,
B. et al. (2011) Synthesis, improved antisense activity and structural rationale for the divergent RNA
affinities of 3’-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem.
Soc., 133, 16642-16649.
34. Burdick, A.D., Sciabola, S., Mantena, S.R., Hollingshead, B.D., Stanton, R., Warneke, J.A., Zeng, M.,
Martsen, E., Medvedev, A., Makarov, S.S., et al. (2014) Sequence motifs associated with hepatotoxicity of
locked nucleic acid--modified antisense oligonucleotides. Nucleic Acids Res., 42, 4882–4891.
35. Hagedorn, P.H., Yakimov, V., Ottosen, S., Kammler, S., Nielsen, N.F., Høg, A.M., Hedtjärn, M.,
Meldgaard, M., Møller, M.R., Orum, H., et al. (2013) Hepatotoxic potential of therapeutic oligonucleotides
can be predicted from their sequence and modification pattern. Nucleic Acid Ther., 23, 302-310.
36. Kakiuchi-Kiyota, S., Koza-Taylor, P.H., Mantena, S.R., Nelms, L.F., Enayetallah, A.E., Hollingshead,
B.D., Burdick, A.D., Reed, L.A., Warneke, J.A., Whiteley, L.O., et al. (2014) Comparison of hepatic
75
transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways
contributing to non-target mediated toxicity in mice. Toxicol. Sci., 138, 234-248.
37. Burel, S.A., Hart, C.E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.H., Younis, H.,
Sabripour, M. et al. (2015) Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated
by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res., 44,
2093-2109.
38. Kamola, P.J., Kitson, J.D., Turner, G., Maratou, K., Eriksson, S., Panjwani, A., Warnock, L.C., Douillard
Guilloux, G.A., Moores, K., Koppe, E.L. et al. (2015) In silico and in vitro evaluation of exonic and intronic
off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res., 43,
8638-8650.
39. Kawai, T. and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in
infection and immunity. Immunity, 34, 637-650.
40. Krieg, A.M., Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A. and
Klinman, D.M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546-549.
41. Kawabata, T., Kinoshita, M., Inatsu, A., Habu, Y., Nakashima, H., Shinomiya, N. and Seki. S. (2008)
Functional alterations of liver innate immunity of mice with aging in response to CpGoligodeoxynucleotide. Hepatology, 48, 1586-1597.
42. Senn, J.J., Burel, S. and Henry, S.P. (2005) Non-CpG-containing antisense 2’-methoxyethyl
oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid
differentiation. J. Phrmacol. Exp. Ther., 314, 972-979.
43. Burel, S.A., Machemer, T., Ragone, F.L., Kato, H., Cauntay, P., Greenlee, S., Salim, A., Gaarde, W.A.,
Hung, G., Peralta, R., Freier, S.M. and Henry, S.P. (2012) Unique O-methoxyethyl ribose-DNA chimeric
oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of
Type I interferon response. J. Phrmacol. Exp. Ther., 342, 150-162.
76
44. Vollmer, J., Jepsen, J.S., Uhlmann, E., Schetter, C., Jurk, M., Wader, T., Wüllner, M. and Krieg, A.M.
(2004) Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid
(LNA). Oligonucleotides, 14, 23-31.
45. Watanabe, T.A., Geary, R.S., Levin, A.A. (2006) Plasma protein binding of an antisense oligonucleotide
targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16, 169-180.
46. Food and Drug Administration Center for Drug evaluation and Research. 2013, Kynamuro (mipomersen
sodium) Injection Pharmacology Review (s). www.accessdata.fda.gov/203568Orig1s000Rems
47. Koczor, C.A., Torres, R.A. and Lewis, W. (2012) The role of transporters in the toxicity of nucleoside
and nucleotide analogus. Expert Opin. Drug Metab. Toxicol., 8, 665-676.
48. Kassel, O. and Herrlich, P. (2007) Crosstalk between the glucocorticoid receptor and other transcription
factors: Molecular aspects. Mol. Cel. Endocrinol., 275, 13-29.
49. LI, L.O., Klett, E.L. and Coleman, R.A. (2010) Acyl-CoA synthesis, lipid metabolism and lipotoxicity.
Biochim. Biophys. Acta., 1801, 246-251.
50. Ohtani, N., Haruki, M., Morikawa, M., Kanaya, S. (1999) Molecular diversities of RNases H. J. Biosci.
Bioeng. 88, 12-29.
51. Rychlik, M., P.; Chon, H., Cerritelli, S.M., Klimek, P., Crouch, R.J., Nowotny, M. (2010) Crystal
structures of RNase H2 in complex with nucleic acid reveal the mechanism of RNA-DNA junction
recognition and cleavage. Molecular. Cell, 40, 658-670.
52. Cerritelli, S.M, Frolova, E.G., Feng, C., Grinberg, A., Love, P.E., Crouch, R.J. (2003) Failure to produce
mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Molecular Cell, 11, 807-815.
53. Akman, G, Frolova, Desai, R., Bailey, L.J., Yasukawa, T., Rosa, I.D. et al. (2016) Pathological
ribonuclease H1 causes R-loop depletion and aberrant DNA segregation in mitochondria. Proc. Natl Acad.
77
Sci. USA, 30, 4276-4285.
54. Reijns, M.A., Rabe, B., Rigby, R.E., Mill, P., Astell, K.R., Lettice LA., Boyle, S., Leitch, A., Keighren,
M., Kilanowski., et al.
(2012) Enzymatic removal of ribonucleotides from DNA is essential for
mammalian genome Integrity and development. Cell, 149, 1008-1022.
55. Hiller, B., Achleitner, M., Glage, S., Naumann, R., Behrendt, R. and Roers, A. (2012) Mammalian
RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J. Exp. Med., 8, 1419-1426.
56. Reijns, M.A., Bubeck, D., Gibson, L.C., Graham, S.C., Baillie, G.S., Jones, E.Y. and Jackson, A.P.
(2011) The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme
function and human disease. J. Biol. Chem., 286, 10530-10539.
57. Crow, Y.J., Leitch, A., Hayward, B.E., Garner, A., Parmar, R., Griffith, E., Ali, M., Semple, C., Aicardi,
J., Babul-Hirji, R., et al. (2006) Mutations in genes encoding ribonuclease H2 subunits cause AicardiGoutie`res syndrome and mimic congenital viral brain infection. Nat. Genet., 38, 910-916.
58. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A, Driver, S.E, Mello, C.C. (1998) Potent and specific
genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
59. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. (2001) Duplexes of 21nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 24, 494-498.
60. Straarup, E.M., Fisker, N., Hedtjärn, M., Lindholm, M.W., Rosenbohm, C., Aarup, V, Hansen, H.F.,
Ørum, H., Hansen, J.B. and Koch, T. (2010) Short locked nucleic acid antisense oligonucleotides potently
reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acid Res.,
38, 7100-7111.
61. Dobie, K.W. and Koller, E. (2006) Inventors; Isis Pharmaceuticals, Inc., assignee. Antisense modulation
of kinesin-like 1 expression. United States patent US 7,163,927.
78
62. Hammond, S.M., Boettcher, S., Caudy, A.A., Kobayashi, R., Hannon, G.J. (2001) Argonaute2, a link
between genetic and biochemical analyses of RNAi. Science, 293, 1146-1150.
63. Hutvagner, G., Simard, M.J. (2008) Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol.
Cell Biol., 9, 22-32.
64. Nair J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy,
P., Kel'in, A.V., Milstein, S., et al. (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes
in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc., 136, 16958-16961.
65. Watanabe, A., Nakajima, M., Kasuya, T., Onishi, R., Kitade, N., Mayumi, K., Ikehara T. and Kugimiya,
A. (2016) Comparative characterization of hepatic distribution and mRNA reduction of antisense
oligonucleotides conjugated with triantennary N-acetyl galactosamine and lipophilic ligands targeting
apolipoprotein B. J. Pharmacol. Exp. Ther., 357, 320-330.
66. Li, O.L., Ellis, M.J., Paich, A.H., Wang, S., Gong, N., Altshuller, G., Thresher, J.R., Koves, R.T.,
Watkins, M.S., Muoio, M.D., Cline, W.G., Shulman, I.G. and Coleman, R.A. (2009) Liver-specific loss of
long chain acyl-coA synthetase-1 decreases triacylglycerol synthesis and -oxidation and alters
phospholipid fatty acid composition. J. Biol. Chem., 284, 27816-27826.
67. Warf, M.B., Berglund, J.A. (2010) Role of RNA structure in regulating pre-mRNA splicing. Trends
Biochem. Sci., 35, 169-178.
68. Kiss, T. (2001) Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO.
J., 20, 3617-22.
69. Berg, J.M., Tymoczko, J.L., Stryer, L. (2007) Biochemistry, 6th edition, WH Freeman & Co.
70. Hutvagner, G., Simard, M.J. (2006) Transport of messenger RNA from the nucleus to the cytoplasm.
Curr. Opin. Cell Biol., 18, 299-306.
79
71. Suzuki, Y., Holmes, J.B., Cerritelli, S.M., Sakhuja, K., Minczuk, M., Holt, I.J. and Crouch, R.J. (2010)
An upstream open reading frame and the context of the two AUG codons affect the abundance of
mitochondrial and nuclear RNase H1. Mol. Cell Biol., 30, 5123-5134.
72. Lindow, M., Vornlocher, HP., Riley, D., Kornbrust, D.J., Burchard, J., Whiteley, L.O., Kamens, J.,
Thompson, J.D., Nochur, S., Younis, H., Bartz, S., Parry, J., Ferrari, N., Henry, S.P., Levin, A.A. (2001)
Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol., 30,
920-923.
73. Birmingham, A., Anderson, E.M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville,
S., Maksimova, E., Robinson, K., Karpilow, J., Marshall, W.S., Khvorova, A. (2006) 3' UTR seed matches,
but not overall identity, are associated with RNAi off-targets. Nat. Methods., 3, 199-204.
74. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G., Linsley,
PS. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
75. Kasuya, T., Kugimiya, A. (2018) Role of Computationally Evaluated Target Specificity in the
Hepatotoxicity of Gapmer Antisense Oligonucleotides. Nucleic Acid Ther., 28, 312-317.
76. Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P.M., Tidow, N., Brandt, B., Buerger,
H., Bulk, E., Thomas, M., Berdel, W.E., Serve, H., Müller-Tidow, C. (2003) MALAT-1, a novel noncoding
RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.
Oncogene, 22, 8031-8041.
77. Hung, G., Xiao, X., Peralta, R., Bhattacharjee, G., Murray, S., Norris, D., Guo, S. and Monia, B.P.
(2013) Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ
systems following systemic antisense treatment in animals. Nucleic Acids Ther., 23, 369-378.
78. Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N., Oyama, R., et al. (2005)
The transcriptional landscape of the mammalian genome. Science, 309, 1559–1563.
80
79. Szymanski, M., Barciszewska, M.Z., Erdmann, V.A., Barciszewski, J. (2005) A new frontier for
molecular medicine: noncoding RNAs. Biochim. Biophys. Acta., 1756, 65–75.
80. Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N., Oyama, R., et al. (2005)
The transcriptional landscape of the mammalian genome. Science, 309, 1559–1563.
81. Yamamoto, T., Yahara, A., Waki, R., Yasuhara, H., Wada, F., Harada-Shiba, M., Obika, S.
(2015)
Amido-bridged nucleic acids with small hydrophobic residues enhance hepatic tropism of antisense
oligonucleotides in vivo. Org. Biomol. Chem., 13, 3757-3765.
82. Hagedorn, P.H., Hansen, B.R., Koch, T and Lindow, M. (2017) Managing the sequence-specificity of
antisense oligonucleotides in drug discovery. Nucleic Acids Res., 45, 2262-2282.
83. Shen, W., De, Hoyos, CL., Migawa, M.T., Vickers, T.A., Sun, H., Low, A., Bell, T.A., Rahdar M.,
Mukhopadhyay, S., et al. (2019) Chemical modification of PS-ASO therapeutics reduces cellular proteinbinding and improves the therapeutic index. Nat. Biotechnol., 37, 640-650.
84. Liang, X.H., Sun, H., Shen, W. & Crooke, S.T. (2015) Identification and characterization of intracellular
proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res., 43, 2927-2945.
85. Shen, W. et al. (2018) Acute hepatotoxicity of 2’ fluoro-modified 5-10-5 gapmer phosphorothioate
oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
Nucleic Acids Res., 46, 2204-2217.
86. Burel, S.A., Han, S.R., Lee, H.S., Norris, D.A., Lee, B.S., Machemer, T., Park, S.Y., Zhou, T., He, G,
et al. (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified
antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus
monkeys. Nucleic Acid Ther., 23, 213–227.
81
...
論文の公開元へ
